Skip to main content

CORRECTION article

Front. Public Health
Sec. Children and Health
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1517339

Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible

Provisionally accepted
Sirin Falconi Sirin Falconi Abiodun Okimi Abiodun Okimi Shaun Wesley Shaun Wesley Pooja Sethi Pooja Sethi PALIIKA DATTA PALIIKA DATTA Kaytlin Krutsch Kaytlin Krutsch *
  • Texas Tech University Health Sciences Center, Lubbock, United States

This article is a correction to:

  1. The concentration of maternal sacubitril/valsartan transferred into human milk is negligible

    1. Read original article

The final, formatted version of the article will be published soon.

    • please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated. In the published article, there was an error. The currently published article does not acknowledge a previously published study. We would like to add the missing data and properly reference the earlier work.A correction has been made to Discussion (first sentence) This sentence previously stated: "There are no previous studies evaluating the transfer of any NEP inhibitor (e.g., sacubitril) or ARB (e.g., valsartan) into human milk, limiting the use of these drug classes in breastfeeding mothers suffering from HF."The corrected sentence appears below: "There are no previous studies evaluating the transfer of any NEP inhibitor (e.g., sacubitril) into human milk. A single case series has reported the limited transfer of one ARB, candesartan, into human milk. This scarcity of data restricts the use of these drug classes in breastfeeding mothers suffering from HF." Ref: Coberger ED, Jensen BP, Dalrymple JM. Transfer of Candesartan Into Human Breast Milk. Obstet Gynecol. 2019;134(3):481-484. doi:10.1097/AOG.0000000000003446

    Keywords: Heart Failure, Entresto, Lactation, Pharmacology, Peripartum cardiomyopathy (PPCM), Maternal health

    Received: 25 Oct 2024; Accepted: 31 Oct 2024.

    Copyright: © 2024 Falconi, Okimi, Wesley, Sethi, DATTA and Krutsch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Kaytlin Krutsch, Texas Tech University Health Sciences Center, Lubbock, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.